UNLABELLED: Serum adiponectin is a risk factor for fracture. The predictive value attenuates with time in elderly men so that its use for the risk assessment in the long term is questionable. The study underlines the importance of testing the long-term stability of potential risk factors. INTRODUCTION: High serum adiponectin is associated with an increased risk of fracture in elderly men. The aim of the present study was to determine the impact of adiponectin on the probability of fracture as a function of time. METHODS: The probability of osteoporotic fracture was computed in 989 elderly men from the MrOS study in Sweden. Baseline data included clinical risk factors for fracture, femoral neck BMD and serum adiponectin. Men were followed for up to 7.4 years with a mean follow up of 5.3 years (range 0.0-7.4 years). Poisson regression was used to model the hazard function for osteoporotic fracture and death to determine the 10 year probability of fracture. RESULTS: During follow up, 124 men sustained one or more osteoporotic fracture. There was a significant interaction between adiponectin and time since baseline (p = 0.026) such that the longer time since baseline, the lower the gradient of fracture risk. When using this interaction in the calculation of 10-year probability of fracture, the probabilities of osteoporotic fracture varied little over the range of adiponectin values. CONCLUSION: Serum adiponectin is a risk factor for fracture. Nevertheless, the predictive value attenuates with time so that its use for the risk assessment in the long term is questionable. This study underlines the importance of testing the long-term stability of potential risk factors that might be used in fracture risk assessment.
UNLABELLED: Serum adiponectin is a risk factor for fracture. The predictive value attenuates with time in elderly men so that its use for the risk assessment in the long term is questionable. The study underlines the importance of testing the long-term stability of potential risk factors. INTRODUCTION: High serum adiponectin is associated with an increased risk of fracture in elderly men. The aim of the present study was to determine the impact of adiponectin on the probability of fracture as a function of time. METHODS: The probability of osteoporotic fracture was computed in 989 elderly men from the MrOS study in Sweden. Baseline data included clinical risk factors for fracture, femoral neck BMD and serum adiponectin. Men were followed for up to 7.4 years with a mean follow up of 5.3 years (range 0.0-7.4 years). Poisson regression was used to model the hazard function for osteoporotic fracture and death to determine the 10 year probability of fracture. RESULTS: During follow up, 124 men sustained one or more osteoporotic fracture. There was a significant interaction between adiponectin and time since baseline (p = 0.026) such that the longer time since baseline, the lower the gradient of fracture risk. When using this interaction in the calculation of 10-year probability of fracture, the probabilities of osteoporotic fracture varied little over the range of adiponectin values. CONCLUSION: Serum adiponectin is a risk factor for fracture. Nevertheless, the predictive value attenuates with time so that its use for the risk assessment in the long term is questionable. This study underlines the importance of testing the long-term stability of potential risk factors that might be used in fracture risk assessment.
Authors: Helena Johansson; Anders Odén; Ulf H Lerner; Hans Jutberger; Mattias Lorentzon; Elizabeth Barrett-Connor; Magnus K Karlsson; Osten Ljunggren; Ulf Smith; Eugene McCloskey; John A Kanis; Claes Ohlsson; Dan Mellström Journal: J Bone Miner Res Date: 2012-06 Impact factor: 6.741
Authors: Eric Orwoll; Janet Babich Blank; Elizabeth Barrett-Connor; Jane Cauley; Steven Cummings; Kristine Ensrud; Cora Lewis; Peggy M Cawthon; Robert Marcus; Lynn M Marshall; Joan McGowan; Kathy Phipps; Sherry Sherman; Marcia L Stefanick; Katie Stone Journal: Contemp Clin Trials Date: 2005-10 Impact factor: 2.226
Authors: Dan Mellström; Olof Johnell; Osten Ljunggren; Anna-Lena Eriksson; Mattias Lorentzon; Hans Mallmin; Anna Holmberg; Inga Redlund-Johnell; Eric Orwoll; Claes Ohlsson Journal: J Bone Miner Res Date: 2006-04-05 Impact factor: 6.741
Authors: H Luukinen; S M Käkönen; K Pettersson; K Koski; P Laippala; T Lövgren; S L Kivelä; H K Väänänen Journal: J Bone Miner Res Date: 2000-12 Impact factor: 6.741
Authors: Kaisa K Ivaska; Paul Gerdhem; H Kalervo Väänänen; Kristina Akesson; Karl J Obrant Journal: J Bone Miner Res Date: 2010-02 Impact factor: 6.741
Authors: Dan Mellström; Liesbeth Vandenput; Hans Mallmin; Anna H Holmberg; Mattias Lorentzon; Anders Odén; Helena Johansson; Eric S Orwoll; Fernand Labrie; Magnus K Karlsson; Osten Ljunggren; Claes Ohlsson Journal: J Bone Miner Res Date: 2008-10 Impact factor: 6.741
Authors: Joshua F Baker; Patricia Katz; David R Weber; Patrick Gould; Michael D George; Jin Long; Babette S Zemel; Jon T Giles Journal: Arthritis Care Res (Hoboken) Date: 2021-09-24 Impact factor: 4.794
Authors: E V McCloskey; J A Kanis; A Odén; N C Harvey; D Bauer; J González-Macias; D Hans; S Kaptoge; M A Krieg; T Kwok; F Marin; A Moayyeri; E Orwoll; C Gluёr; H Johansson Journal: Osteoporos Int Date: 2015-02-18 Impact factor: 4.507